Medikamentöse Therapie der Hypercholesterinämie

Deutsche Medizinische Wochenschrift

Volumn 121, Issue 22, 1996, Pages 729-734

  Berthold, H K ^a   Von Bergmann, K ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; COLESTIPOL; COLESTYRAMINE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; HYPOCHOLESTEROLEMIC AGENT;

AGE; ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIET; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; RISK FACTOR; SHORT SURVEY; SMOKING; ADULT; AGED; ARTERIOSCLEROSIS; FEMALE; MALE; MIDDLE AGED; REVIEW;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; CORONARY DISEASE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; RISK FACTORS;

EID: 0029989793     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1043062     Document Type: Article

References (30)

1. Anderson, T. J., I. T. Meredith, A. C. Yeung, B. Frei, A. P. Selwyn, P. Ganz: The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. New Engl. J. Med. 332 (1995), 488-493.
2. Andrade, S. E., A. M. Walker, L. K. Gottlieb, N. K. Hollenberg, M. A. Testa, G. M. Saperia, R. Platt: Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? New Engl. J. Med. 332 (1995), 1125-1131.
3. Becker, M., D. Staab, K. von Bergmann: Treatment of severe familial hypercholesterolemia in childhood with sitosterol and sitostanol. J. Pediat. 122 (1993), 292-296.
4. Blankenhorn, D. H., S. P. Azen, D. P. Kramsch, W. J. Mack, L. Cashin-Hemphill, H. N. Hodis, L. W. V. DeBoer, P. R. Mahrer, R. J. Masteller, L. I. Vailas, P. Alavpovic, L. J. Hirsch, T. M. R. Group: Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann. intern. Med. 119 (1993), 969-976.
5. Brown, G., J. J. Albers, L. D. Fisher, S. M. Schaefer, J.-T. Lin, C. Kaplan, X.-Q. Zhao, B. D. Bisson, V. F. Fitzpatrick, H. T. Dodge: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. New Engl. J. Med. 323 (1990), 1289-1298.
6. Canner, P. L., K. G. Berge, N. K. Wenger, J. Stamler, L. Friedman, R. J. Prineas, W. Friedewald, The Coronary Drug Project Research Group: Fifteen year mortality in coronary drug project patients. Long-term benefit with niacin. J. Amer. Coll. Cardiol. 8 (1986), 1245-1255.
7. Crouse III, J. R., R. P. Byington, M. G. Bond, M. A. Espeland, T. E. Craven, J. W. Sprinkle, M. E. McGovern, C. D. Furberg: Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Amer. J. Cardiol. 75 (1995), 455-459.
8. Frick, M. H., O. Elo, K. Haapa, O. P. Heinonen, P. Heinsalmi, P. Helo, J. K. Huttunen, P. Kaitaniemi, P. Koskinen, V. Manninen, H. Mäenpää, M. Mälkönen, M. Mänittäri, S. Norola, A. Pasternack, J. Pikkarainen, M. Romo, T. Sjöblom, E. A. Nikkilä: Helsinki heart study. Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. New Engl. J. Med. 317 (1987), 1237-1245.
9. Furberg, C. D., H. P. Adams, W. B. Applegate, R. P. Byington, M. A. Espeland, T. Hartwell, D. B. Hunnunghake, D. S. Lefkowitz, J. Probstfield, W. A. Riley, B. Young: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 90 (1994), 1679-1687.
10. Gould, A. L., J. E. Rossouw, N. C. Santanello, J. F. Heyse, C. D. Furberg: Cholesterol reduction yields clinical benefit. A new look at old data. Circulation 91 (1995), 2274-2282.
11. Haskell, W. L., E. L. Alderman, J. M. Fair, D. J. Maron, S. F. Mackey, R. Superko, P. T. Williams, I. M. Johnstone, M. A. Champagne, R. M. Krauss, J. W. Farquhar: Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 89 (1994), 975-990.
12. Havel, R. J., E. Rapaport: Management of primary hyperlipidemia. New Engl. J. Med. 332 (1995), 1491-1498.
13. Kane, J. P., M. J. Malloy, T. A. Ports, T. R. Phillips, J. C. Diehl, R. J. Havek: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. J. Amer. med. Ass. 264 (1990), 3007-3012.
14. Kobashigawa, J. A., S. Katznelson, H. Laks, J. A. Johnson, L. Yeatman, X. M. Wang, D. Chia, P. I. Terasaki, A. Sabad, G. A. Cogert, K. Trosian, M. A. Hamilton, J. D. Moriguchi, N. Kawata, A. Hage, D. C. Drinkwater, L. W. Stevenson: Effect of pravastatin on outcomes after cardiac transplantation. New Engl. J. Med. 333 (1995), 621-627.
15. Kronmal, R. A., K. C. Cain, Z. Ye, C. S. Omenn: Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. Arch. intern. Med. 153 (1993), 1065-1073.
16. Levine, G. N., J. F. Keaney jr., J. A. Vita: Cholesterol reduction in cardiovascular disease. New Engl. J. Med. 332 (1995), 512-521.
17. Loscalzo, J.: Regression of coronary atherosclerosis. New Engl. J. Med. 323 (1990), 1337-1339.
18. MAAS investigators: Effect of simvastatin on coronary atheroma. The Multicentre Anti-Atheroma Study (MAAS). Lancet 344 (1994), 633-638.
19. Miettinen, T. A., P. Puska, H. Gylling, H. Vanhanen, E. Vartiainen: Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. New Engl. J. Med. 333 (1995), 1308-1312.
20. National Cholesterol Education Program: Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II), Second Report of the Expert Panel (S.M. Grundy, Chairman). Circulation 89 (1994), 1329-1445.
21. Ornish, D., S. E. Brown, L. W. Scherwitz, J. H. Billings, W. T. Armstrong, T. A. Ports, S. M. McLanahan, R. L. Kirkeeide, R. J. Brand, K. L. Gould: Can lifestyle changes reverse coronary heart disease? The lifestyle heart trial. Lancet 336 (1990), 129-133.
22. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994), 1383-1389.
23. Schuler, G., R. Hambrecht, G. Schlierf, J. Niebauer, E. Hoberg, A. Drinkmann, F. Bacher, M. Grunze, W. Kubler: Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. Circulation 86 (1992), 1-11.
24. Shepherd, J., S. M. Cobbe, I. Ford, C. G. Isles, A. R. Lorimer, P. W. Macfarlane, J. H. McKillop, C. J. Packard: West Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl. J. Med. 333 (1995), 1301-1307.
25. The International Task Force for Prevention of Coronary Heart Disease: Prevention of coronary heart disease. Scientific background and new clinical guidelines. Recommendations of the European Atherosclerosis Society. Nutr. Metab. cardiovasc. Dis. 2 (1992), 113-156.
26. Treasure, C. B., J. L. Klein, W. S. Weintraub, J. D. Talley, M. E. Stillabower, A. S. Kosinski, J. Zhang, S.J. Boccuzzi, J. C. Cedarholm, R. W. Alexander: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. New Engl. J. Med. 332 (1995), 481-487.
27. Vita, J. A., C. B. Treasure, E. G. Nabel, J. M. McLenachan, R. D. Fish, A. C. Yeung, V. I. Vekshtein, A. P. Selwyn, P. Ganz: Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 81 (1990), 491-497.
28. Waters, D., L. Higginson, P. Gladstone, B. Kimball, M. Le May, S. J. Boccuzzin, J. Lespérance, T. C. S. Group: Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial artheriography. The Canadian Coronary Atheroclerosis Intervention Trial. Circulation 89 (1994), 959-968.
29. Watts, G. F., B. Lewis, J. N. H. Brunt, E. S. Lewis, D. J. Cotart, L. D. R. Smith, J. I. Mann, A. V. Swan: Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet 339 (1992), 563-569.
30. Yusuf, S., J. Wittes, L. Friedman: Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. J. Amer. med. Ass. 260 (1988), 2259-2263.